Last reviewed 2026-04-20 · How we verify

nitenpyram

FDA-approved active Quality 10/100

nitenpyram is a drug. It is currently FDA-approved.

At a glance

Generic name	nitenpyram
Target	Acetylcholine receptor subunit beta-like 2
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

nitenpyram CI brief — competitive landscape report
nitenpyram updates RSS · CI watch RSS
portfolio CI

Frequently asked questions about nitenpyram

What is nitenpyram?

nitenpyram is a pharmaceutical drug.

What development phase is nitenpyram in?

nitenpyram is FDA-approved (marketed).

What does nitenpyram target?

nitenpyram targets Acetylcholine receptor subunit beta-like 2.

Target: All drugs targeting Acetylcholine receptor subunit beta-like 2
Manufacturer: — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing